Anlotinib相关论文
目的探讨125I粒子植入联合盐酸安罗替尼在非小细胞肺癌（NSCLC）治疗中的临床疗效。方法纳入61例NSCLC患者，其中30例（观察组）接受125I粒子......
1例69岁男性患者因腹膜后肉瘤接受安罗替尼胶囊（12 mg口服、1次/d，服用14 d，停药7 d）和信迪利单抗注射液（200 mg静脉滴注、第1天）方案治......
目的评价新型口服多靶点酪氨酸激酶抑制剂(TKI)安罗替尼治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法实验性研究。通过检索Pu......
1例64岁女性患者因直肠腺癌伴双肺多发转移行直肠癌根治术，术后接受奥沙利铂联合卡培他滨治疗无效，改用安罗替尼12 mg/d口服，治疗2周，......
目的探讨安罗替尼联合伊立替康三线治疗转移性食管癌的临床疗效及不良反应。方法选取2018年10月至2019年10月安徽省六安市中医院收......
Efficacy and safety of anlotinib plus S-1 as thirdly-line or later-line treatment in advanced non-sm
Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, has confirmed antitumor a......
Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activa
Objective: Bevacizumab is a recombinant humanized monoclonal antibody that blocks vascular endothelial growth factor (VE......
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a pro
Objective: Lymphatic metastasis is one of the leading causes of malignancy dispersion in various types of cancer. Howeve......
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or f
Objective: Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth f......
目的评价安罗替尼对比多西他赛用于一线治疗失败的晚期非小细胞肺癌(NSCLC)的疗效及安全性,探讨安罗替尼用于二线治疗晚期NSCLC的......
